Leukemia treatment: types, options and what patients need to know
Leukemia is one of the most common blood cancers worldwide, affecting both children and adults. Yet despite its complexity, leukemia treatment has advanced dramatically over the past two decades, with survival rates improving significantly thanks to chemotherapy, targeted therapy, immunotherapy and stem cell transplantation.
Whether you have just been diagnosed with acute lymphocytic leukemia (ALL),chronic myeloid leukemia (CML),or another form of blood cancer, understanding your treatment options is the first step toward effective care.
At Biruni Hospital in Turkey, a multidisciplinary team of expert hematologists and oncologists designs personalized treatment plans for every type and stage of leukemia, combining the latest therapies with compassionate, patient-centered support.
This complete guide covers everything you need to know about leukemia treatment : types, diagnosis, therapy options, survival rates and what life looks like during and after treatment.
Types of leukemia: acute and chronic forms explained
Leukemia is a type of blood cancer that develops in the bone marrow when abnormal blood cells begin to multiply uncontrollably, understanding its different forms is essential for accurate diagnosis, treatment planning and prognosis.
Leukemia is primarily classified along two axes : how quickly it progresses (acute or chronic) and which type of blood cell is affected (lymphocytic or myeloid).
Acute leukemia: rapid onset and urgent treatment
Acute leukemia progresses rapidly, often within days or weeks. It affects immature blood cells called blast cells that multiply uncontrollably and quickly crowd out healthy red blood cells, white blood cells and platelets in the bone marrow.
Symptoms appear suddenly and can be severe :
Extreme fatigue and pallor linked to anemia
High fever and recurrent infections due to a weakened immune system
Easy bruising, petechiae or unexplained bleeding caused by low platelet counts (thrombocytopenia)
Bone pain, swollen lymph nodes or enlarged liver and spleen in some cases
Because acute leukemia can deteriorate rapidly, prompt diagnosis and immediate treatment, typically starting with induction chemotherapy, are critical to prevent life-threatening complications such as severe infections, organ damage or blast crisis.
ALL and AML: the two main subtypes of acute leukemia
Acute leukemia is divided into two primary subtypes based on the type of blood cell involved :
Acute Lymphocytic Leukemia (ALL) : originates in lymphoid cells, the white blood cells responsible for immune responses. It is the most common cancer in children, representing the majority of pediatric leukemia cases, but it can also affect adults.
Treatment typically involves intensive induction chemotherapy, followed by consolidation and maintenance therapy. In certain cases of ALL, particularly those involving the Philadelphia chromosome (BCR-ABL mutation),targeted therapy with tyrosine kinase inhibitors such as imatinib is added to the treatment protocol.
Acute Myeloid Leukemia (AML) : develops in myeloid cells, which normally mature into red blood cells, white blood cells or platelets. It is more frequently diagnosed in adults and generally requires intensive chemotherapy.
A specific subtype, Acute Promyelocytic Leukemia (APL),is treated with all-trans retinoic acid (ATRA) combined with chemotherapy, achieving high remission rates. Stem cell transplantation may be recommended for high-risk or relapsed AML cases.
Chronic leukemia: slow progression and long-term management
Chronic leukemia develops slowly, sometimes over months or even years, and may produce no noticeable symptoms in its early stages. It is frequently discovered incidentally during routine blood tests showing an abnormal white blood cell count.
When symptoms do appear, they tend to be gradual :
Persistent fatigue and reduced energy
Mild or recurrent infections
Swollen lymph nodes or enlarged spleen
Unexplained weight loss or night sweats
Unlike acute forms, chronic leukemias can often be managed over the long term, allowing many patients to maintain a good quality of life. Treatment may not be required immediately in some cases, particularly for early-stage chronic lymphocytic leukemia (CLL),where a watch-and-wait approach under close medical supervision is sometimes recommended.
CLL and CML: the two main subtypes of chronic leukemia
Chronic Lymphocytic Leukemia (CLL) : affects lymphoid cells and is the most common leukemia in adults over 60. In early stages, active monitoring without immediate treatment (watch and wait) is often sufficient.
When treatment becomes necessary, options include targeted therapy, immunotherapy with monoclonal antibodies, or chemotherapy depending on disease progression and genetic mutations.
Chronic Myeloid Leukemia (CML) : develops in myeloid cells and is strongly associated with the Philadelphia chromosome, a chromosomal translocation that produces the BCR-ABL fusion gene. This abnormality drives uncontrolled cell proliferation and is the primary target of tyrosine kinase inhibitors such as imatinib (Gleevec) and dasatinib. These targeted therapies have transformed CML from a life-threatening disease into a manageable chronic condition for the majority of patients, with excellent long-term survival rates.
Other leukemia subtypes worth knowing
Beyond the four main types, several rarer forms of leukemia require specialized treatment approaches :
Hairy cell leukemia, a rare slow-growing subtype of B-cell leukemia, is named after the hair-like projections visible on its malignant cells under a microscope.
Adult T-cell leukemia, associated with the HTLV-1 virus and primarily affecting T-lymphocytes.
Myelodysplastic syndromes (MDS), sometimes considered pre-leukemic conditions that can evolve into AML if left untreated.
Understanding the exact type and subtype of leukemia, including its genetic mutations and chromosomal abnormalities, allows hematologists to design the most targeted and effective treatment strategy for each patient.
How is leukemia diagnosed? Tests, procedures and what to expect
Early and accurate diagnosis is the foundation of effective leukemia treatment. The sooner the disease is identified, its type confirmed and its genetic profile mapped, the faster a personalized treatment plan can be put in place.
At Biruni Hospital in Turkey, expert hematologists use a comprehensive set of advanced diagnostic tools to detect leukemia promptly and precisely, from the initial blood test to molecular genetic analysis.
Physical examination : the first step in diagnosing leukemia
The diagnostic process begins with a thorough physical examination. Doctors look for visible and palpable signs that may indicate abnormal blood cell production or leukemia-related complications :
Swollen lymph nodes in the neck, armpits or groin
An enlarged spleen (splenomegaly) or enlarged liver (hepatomegaly)
Unusual bruising, petechiae (small red or purple spots under the skin) or unexplained bleeding
Pallor, bone pain or signs of recurrent infection
These clinical findings guide the selection of further diagnostic tests and help narrow down the suspected leukemia type.
Blood tests : detecting abnormal white blood cell counts
Blood tests are typically the first laboratory investigations ordered when leukemia is suspected.
Complete Blood Count (CBC) : measures the levels of red blood cells, white blood cells and platelets circulating in the bloodstream. In leukemia, the CBC typically reveals one or more of the following abnormalities :
Elevated or significantly reduced white blood cell count
Low red blood cell count, indicating anemia
Low platelet count (thrombocytopenia),increasing the risk of bleeding
Peripheral Blood Smear : involves examining a sample of blood under a microscope to assess the shape, size and maturity of blood cells. The presence of blast cells or other morphologically abnormal cells in the bloodstream is a strong indicator of acute leukemia or other hematologic malignancies.
Bone marrow tests : confirming the diagnosis
Because leukemia originates in the bone marrow, a direct examination of bone marrow tissue is essential to confirm the diagnosis, determine the leukemia subtype and assess disease severity.
Bone Marrow Aspiration and Biopsy : involves collecting a small sample of bone marrow, usually from the hip bone, using a thin needle. The sample is then analyzed to :
Confirm the presence and percentage of leukemic or blast cells
Identify the specific leukemia type (ALL, AML, CLL, CML or rarer subtypes)
Evaluate how extensively the disease has affected normal blood cell production
Genetic Testing and Cytogenetics : are performed on bone marrow or blood samples to detect chromosomal abnormalities, mutations and translocations at a molecular level. Key findings include the following:
The Philadelphia chromosome (BCR-ABL translocation),which is characteristic of CML and a subset of ALL cases, and directly guides the use of tyrosine kinase inhibitors such as imatinib or dasatinib
FLT3, NPM1 and IDH mutations in AML, which influence treatment selection and prognosis
Flow cytometry (cytometry) for immunophenotyping, identifying the exact cell type involved and confirming the leukemia subtype
Minimal residual disease (MRD) testing after treatment begins, to measure how well the therapy is working at a molecular level
Lumbar puncture : checking for central nervous system involvement
In certain leukemia types, particularly ALL, leukemic cells can spread to the cerebrospinal fluid surrounding the brain and spinal cord. A lumbar puncture (spinal tap) is performed to collect and analyze the spinal fluid for the presence of leukemia cells. If central nervous system involvement is confirmed, intrathecal chemotherapy, delivered directly into the spinal fluid, is added to the treatment protocol.
Imaging tests : assessing organ involvement
CT scans, X-rays and ultrasounds complement the laboratory findings by providing a visual assessment of the body. These imaging tests help detect :
Organ enlargement, such as an enlarged spleen or liver
Swollen lymph nodes or masses in the chest or abdomen
Complications related to leukemia progression or infection
Together, these diagnostic tools provide a complete clinical and molecular picture of the disease, allowing hematologists to determine the most appropriate and personalized leukemia treatment strategy from the very first consultation.
Leukemia prognosis and survival rates: what patients can expect
The outlook for people diagnosed with leukemia has improved considerably over the past two decades, thanks to advances in targeted therapy, immunotherapy, stem cell transplantation and a deeper understanding of the genetic drivers of the disease. While prognosis varies significantly depending on several individual factors, early diagnosis and access to personalized leukemia treatment remain the two most powerful predictors of a positive outcome.
Key factors that influence leukemia prognosis
No two leukemia cases are identical. Several clinical and biological elements shape how a patient responds to treatment and what their long-term outlook looks like :
Type and subtype of leukemia : Acute forms such as ALL and AML progress rapidly and require immediate intensive treatment, but they can also respond dramatically to therapy, particularly in children. Chronic forms such as CLL and CML tend to progress slowly and are often manageable over many years with targeted therapies, allowing patients to maintain near-normal quality of life.
Age and overall health : Younger patients and those with good baseline health generally tolerate intensive chemotherapy or stem cell transplantation better and tend to achieve higher remission rates. In elderly patients or those with significant comorbidities, treatment plans are carefully adjusted to balance efficacy with tolerability.
Genetic mutations and chromosomal abnormalities : The molecular profile of leukemia cells is one of the strongest prognostic indicators available today. Key findings include the following:
The Philadelphia chromosome (BCR-ABL translocation) in CML and some ALL cases, which predicts a strong response to tyrosine kinase inhibitors such as imatinib and dasatinib
Favorable cytogenetic changes in AML that are associated with higher remission rates
High-risk mutations such as FLT3-ITD in AML, which may require more aggressive treatment or stem cell transplantation
Minimal residual disease (MRD) status after induction therapy, which is now used as a real-time indicator of treatment effectiveness and relapse risk
Response to treatment : Patients who achieve complete remission after induction chemotherapy, and who maintain that remission through consolidation and maintenance therapy, consistently show better long-term survival. Regular follow-up and adherence to the full treatment protocol are essential to reducing the risk of relapse or refractory disease.
Survival rates by leukemia type
While survival statistics reflect population-level data and individual outcomes can differ significantly, understanding general survival trends helps patients and families set realistic expectations and make informed decisions.
ALL (Acute Lymphocytic Leukemia) : Childhood ALL has one of the highest cure rates of any cancer, with long-term survival rates exceeding 90% in children treated at specialized centers. In adults, survival rates are lower but have improved steadily with the introduction of targeted therapies and CAR-T cell therapy for relapsed or refractory cases. check our article about " signs of leukemia in children "
AML (Acute Myeloid Leukemia) : AML prognosis varies widely depending on genetic subtype and patient age. Patients with favorable cytogenetics who receive timely induction chemotherapy followed by consolidation, and stem cell transplantation where indicated, can achieve long-term remission. Acute promyelocytic leukemia (APL) in particular has become one of the most curable forms of AML, with remission rates above 90% using all-trans retinoic acid (ATRA) combined with chemotherapy.
CLL (Chronic Lymphocytic Leukemia) : CLL is the most common leukemia in adults and tends to progress slowly. Many patients live for a decade or more after diagnosis. In early stages, a watch-and-wait approach is often appropriate. When treatment becomes necessary, targeted therapies and monoclonal antibodies have significantly extended survival and quality of life.
CML (Chronic Myeloid Leukemia) : The introduction of tyrosine kinase inhibitors such as imatinib (Gleevec) and dasatinib has transformed CML into a chronic manageable condition for the vast majority of patients. Many CML patients treated with TKIs achieve deep molecular remission and maintain it long-term, with life expectancy approaching that of the general population.
want to know more about the curability of leukemia? check our article “ Is leukemia curable? understanding the basics
Why leukemia treatment in Turkey improves outcomes
Access to cutting-edge leukemia treatment in Turkey plays a meaningful role in improving patient prognosis. At Biruni Hospital, patients benefit from :
A multidisciplinary team of expert hematologists and oncologists who design individualized treatment strategies
Advanced stem cell transplantation and bone marrow transplant capabilities, including both autologous and allogeneic procedures
Access to the latest targeted therapies, CAR-T cell therapy and clinical trials for relapsed or refractory leukemia
State-of-the-art molecular diagnostics including MRD monitoring, cytogenetics and flow cytometry
Comprehensive supportive care and long-term follow-up to monitor for recurrence and manage late treatment effects
Early diagnosis, precise molecular profiling and a personalized treatment approach are the cornerstones of improved leukemia survival. The earlier a patient is evaluated and treated by an experienced team, the greater the chances of achieving complete and lasting remission.